TYGACIL's oppositions filed in EPO
TYGACIL Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9254328 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(2 years from now) | |
| US9694078 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(2 years from now) | |
| US10588975 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(2 years from now) | |
| US8975242 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Oct, 2028
(5 years from now) | |
| US7879828 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Feb, 2029
(5 years from now) | |
| US8372995 | PF PRISM CV | Crystalline solid forms of tigecycline and methods of preparing same |
Oct, 2030
(7 years from now) | |
Tygacil is owned by Pf Prism Cv.
Tygacil contains Tigecycline.
Tygacil has a total of 6 drug patents out of which 0 drug patents have expired.
Tygacil was authorised for market use on 15 June, 2005.
Tygacil is available in powder;intravenous dosage forms.
The generics of Tygacil are possible to be released after 08 October, 2030.
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 15 June, 2005
Treatment: NA
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
TYGACIL family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic